MarketPulse

Phase 3 trial failure

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Ultragenyx Stock Crashes 42% After Setrusumab Failure; Class Action Deadline Looms

Ultragenyx faces securities lawsuit after setrusumab Phase 3 trial failure. Stock fell 42%. Investors must apply for class action lead plaintiff status by April 6, 2026.
RAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Vistagen Faces Class Action Lawsuit Over Failed Trial, Stock Crashes 80%

Class action lawsuit filed against Vistagen Therapeutics after Phase 3 trial failure causes 80% stock plunge. Investors have until March 16, 2026 deadline.
VTGNclass action lawsuitmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Ultragenyx Hit With Securities Lawsuit After Setrusumab Trial Failure Tanks Stock 42%

Law firm Kahn Swick & Foti files class action against $UGXX over failed Phase 3 trial for rare bone disease drug setrusumab. Investors can apply as lead plaintiffs by April 6.
KDNAVNRAREsecurities fraudclass action lawsuit
BenzingaBenzinga··Vandana Singh

Theravance Biopharma Crashes 27% After Phase 3 Study Failure

Theravance Biopharma shares plummet 27% after ampreloxetine fails Phase 3 trial; company cuts workforce 50% and reduces expenses 60%.
TBPHstrategic reviewbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Vistagen Faces Securities Fraud Lawsuit Over Failed Phase 3 Trial Results

Vistagen faces class action lawsuit for securities fraud after its Phase 3 trial failed, causing stock to plummet 80%. Investors allege misleading statements about trial progress.
VTGNsecurities fraudclass action lawsuit